Regencell Bioscience [RGC] vs Zoetis [ZTS] Detailed Stock Comparison

Regencell Bioscience Holdings Ltd.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Regencell Bioscience Holdings Ltd. wins in 3 metrics, Zoetis Inc. wins in 12 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Regencell Bioscience Holdings Ltd. Zoetis Inc. Better
P/E Ratio (TTM) -3,258.62 19.58 Zoetis Inc.
Price-to-Book Ratio 2,929.00 15.04 Zoetis Inc.
Debt-to-Equity Ratio 11.20 279.59 Regencell Bioscience Holdings Ltd.
PEG Ratio N/A 2.81 N/A
EV/EBITDA -3,921.47 13.96 Zoetis Inc.
Profit Margin (TTM) 0.00% 28.24% Zoetis Inc.
Operating Margin (TTM) 0.00% 34.69% Zoetis Inc.
EBITDA Margin (TTM) N/A 34.69% N/A
Return on Equity -54.81% 65.99% Zoetis Inc.
Return on Assets (TTM) -33.20% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $-4.01M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 20.24% -51.58% Regencell Bioscience Holdings Ltd.
Price-to-Sales Ratio (TTM) N/A 5.26 N/A
Enterprise Value $14.48B $56.75B Zoetis Inc.
EV/Revenue Ratio N/A 6.00 N/A
Gross Profit Margin (TTM) N/A 70.17% N/A
Revenue per Share (TTM) $0 $21 Zoetis Inc.
Earnings per Share (Diluted) $-0.01 $6.02 Zoetis Inc.
Beta (Stock Volatility) 2.25 0.97 Zoetis Inc.
Short % of Float 1.26% 4.06% Regencell Bioscience Holdings Ltd.

Regencell Bioscience Holdings Ltd. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

RGC
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Regencell Bioscience Holdings Ltd.-9.24%-20.10%-40.20%-24.65%-0.98%-16.80%
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Regencell Bioscience Holdings Ltd.20.24%2,888.89%6,625.00%6,625.00%6,625.00%6,625.00%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: Regencell Bioscience Holdings Ltd. vs Zoetis Inc.

MetricRGCZTS
Market Information
Market Cap i$14.00B$49.75B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i105,4782,727,710
90 Day Avg. Volume i162,7433,835,940
Last Close$17.09$167.10
52 Week Range$9.39 - $83.60$139.70 - $200.33
% from 52W High-79.56%-16.59%
All-Time High$950.00 (May 30, 2025)$249.27 (Dec 27, 2021)
% from All-Time High-98.20%-32.96%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A0.04%
Financial Health
Profit Margin (TTM) i0.00%0.28%
Operating Margin (TTM) i0.00%0.35%
Return on Equity (TTM) i-0.55%0.66%
Debt to Equity (MRQ) i11.20279.59
Cash & Liquidity
Book Value per Share (MRQ)$0.01$7.84
Cash per Share (MRQ)$0.01$5.48
Operating Cash Flow (TTM) i$-3,113,576$2.90B
Levered Free Cash Flow (TTM) i$-1,507,277$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Regencell Bioscience Holdings Ltd. vs Zoetis Inc.

MetricRGC (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i-3,258.6219.58
Forward P/E iN/A15.61
PEG Ratio iN/A2.81
Price to Sales (TTM) iN/A5.26
Price to Book (MRQ) i2,929.0015.04
Market Capitalization
Market Capitalization i$14.00B$49.75B
Enterprise Value i$14.48B$56.75B
Enterprise Value Metrics
Enterprise to Revenue iN/A6.00
Enterprise to EBITDA i-3,921.4713.96
Risk & Other Metrics
Beta i2.250.97
Book Value per Share (MRQ) i$0.01$7.84

Financial Statements Comparison: Regencell Bioscience Holdings Ltd. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRGC (2024)ZTS (2025)
Revenue/Sales i09.47B
Cost of Goods Sold iN/A2.67B
COGS % of Revenue i-28.2%
Gross Profit iN/A6.80B
Gross Margin i-71.8%
Research & Development i1.07M698.00M
Operating Income (EBIT) i-4.74M3.60B
Operating Margin i-38.0%
EBITDA i-3.99M4.17B
EBITDA Margin i-44.1%
Pre-Tax Income i-4.36M3.36B
Pre-Tax Income % of Revenue i-35.5%
Income Tax i0687.00M
Income Tax % of Revenue i-7.3%
Net Income (Profit) i-4.36M2.67B
Profit Margin i-28.2%

Balance Sheet & Liquidity Metrics

MetricRGC (2024)ZTS (2025)
Cash & Equivalents i2.96M2.31B
Total Current Assets i8.11M6.77B
Total Current Assets % of Revenue i-71.5%
Total Current Liabilities i193,5782.24B
Total Current Liabilities % of Revenue i-23.6%
Long-Term Debt i25,9349.24B
Long-Term Debt % of Revenue i-97.6%
Total Shareholders Equity i8.22M3.33B
Retained Earnings i-21.62M13.74B
Retained Earnings % of Revenue i-145.2%
Property, Plant & Equipment i84,780288.00M

Cash Flow Statement Comparison

MetricRGC (2024)ZTS (2025)
Operating Cash Flow i-3.88M2.78B
Operating Cash Flow % of Revenue i-29.3%
Capital Expenditures i-5,376N/A
Free Cash Flow i-4.01M2.28B
FCF Margin i-24.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase iN/A-3.24B

Short Interest & Institutional Ownership Analysis

MetricRGCZTS
Shares Short i700,50915.12M
Short Ratio i5.623.60
Short % of Float i1.26%4.06%
Shares Outstanding i494.49M424.93M
Float Shares i43.94M421.29M
% Held by Insiders i88.56%0.15%
% Held by Institutions i0.12%101.50%
% Held by Public i11.32%-1.65%

Dividend Analysis & Yield Comparison: Regencell Bioscience Holdings Ltd. vs Zoetis Inc.

MetricRGCZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026